Consolidated Statements of Cash Flows Statement (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net income (loss) including noncontrolling interests in operating subsidiaries	$ 49,567,000	$ 25,941,000
Adjustments to reconcile net income including noncontrolling interests in operating subsidiaries to net cash provided by operating activities:
Depreciation and amortization	21,034,000	8,393,000
Non-cash stock compensation	17,375,000	9,891,000
Change in valuation allowance	(10,237,000)	0
Other	490,000	(15,000)
Changes in assets and liabilities:
Accounts receivable	(13,720,000)	(24,573,000)
Prepaid expenses and other assets	(1,485,000)	949,000
Accounts payable and accrued expenses / costs	2,690,000	(737,000)
Royalties and contingent legal fees payable	(2,030,000)	24,290,000
Deferred income tax	(6,546,000)	0
Net cash provided by operating activities	70,230,000	44,139,000
Cash flows from investing activities:
Purchases of property and equipment	(200,000)	(172,000)
Purchase of available-for-sale investments	(305,007,000)	(8,427,000)
Maturities and sale of available-for-sale investments	169,016,000	60,000
Purchase of ADAPTIX, Inc., net of cash acquired	(150,000,000)	0
Patent acquisition costs	(64,960,000)	(2,805,000)
Net cash used in investing activities	(351,151,000)	(11,344,000)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	218,983,000	175,232,000
Distributions to noncontrolling interests in operating subsidiary	(312,000)	(2,897,000)
Contributions from noncontrolling interests in operating subsidiary	3,840,000	877,000
Excess tax benefits from stock-based compensation	7,554,000	1,730,000
Proceeds from exercises of stock options	274,000	411,000
Net cash provided by financing activities	230,339,000	175,353,000
(Decrease) increase in cash and cash equivalents	(50,582,000)	208,148,000
Cash and cash equivalents, beginning	314,733,000	102,515,000
Cash and cash equivalents, ending	$ 264,151,000	$ 310,663,000